Drugs / allogeneic, donor-derived NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02477787 | Jun 2015 → Jun 2019 | acute myeloid leukemia | Asan Medical Center | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic, donor-derived NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02477787 ↗ |
| Modality | Cell therapy | “donor NK cells will be generated from the hematopoietic cells” NCT02477787 ↗ |